Mead Johnson Nutritionals Spinoff IPO

Mead Johnson is finally ready for the market. A spinoff from Bristol Myers Squibb that I think is interesting and will do well.

I’ll have to try and read the prospectus quickly.

Here is a short article from seeking alpha with some details and one from Forbes.

Mead Johnson will start trading on Wednesday under MJN.

Have you read up on Mead Johnson? What do you think?

What is Old School Value?

Old School Value is a suite of value investing tools designed to fatten your portfolio by identifying what stocks to buy and sell.

It is a stock grader, value screener, and valuation tools for the busy investor designed to help you pick stocks 4x faster.

Check out the live preview of AMZN, MSFT, BAC, AAPL and FB.

6 responses to “Mead Johnson Nutritionals Spinoff IPO”

  1. Andrei says:

    Hi Jae,

    As i’ve discussed with you, I think MJN is in a great line of business. The fact that it is a spin-off makes it all the more intriguing because of how spin-offs typically outperform in the first couple of years. However, more than a spin-off, I view MJN as a long-term holding.

    Now if only I could get in at the IPO price :). I’ll have to see how it trades tomorrow and try to get in at a reasonable price.

  2. Jae Jun says:

    I think BMY may also be worth looking at. Since a spinoff is always a result of trying to let the public see under appreciated value, BMY valuation may improve. They still own a majority stake in MJN and with a yield of over 5%, it is a worthy consideration.

  3. PlanMaestro says:

    I would say this lloks more like an IPO than a Spinoff. There is no distribution of shares so most of the reasons described in “You can be a stock market genius” do not apply.

    The greatest beneficiary will probably be the parent.

  4. Jae Jun says:

    Trying to figure out how to put a value on MJN. There doesn’t seem to be a public competitor except ABT, but pediatric nutrition is only one division making it hard to calculate and organise numbers.

    Their history is too short to come up with a reliable forward looking estimate.

    So the multiple method, DCF and Graham methods are all out. What other way is there?

    Anyone know?

  5. Jim says:

    @Jae, I don’t know for certain how to approach ABT other than book value minus all intangibles or the EPV valuation that is used by Bruce Greenwald that uses FCF but doesn’t project its numbers out for a period of time.

    Jim’s last blog post..Axcelis Technology, Inc. Continuation…

  6. Jae Jun says:

    Darn.. Jim I accidently lost your comment again. Sorry. I’m having bad days lately.

    My friend bought Greenwald’s book and I’ll be borrowing it off him. Im keen to get EPV under my belt as well as other techniques to figure out how to value companies such as MJN that are recent spinoffs with no real public competitor.

Pick Winning Stocks and Fatten Your Portfolio